Longeveron Secures U.S. Patent for Method To Treat Aging-Related Frailty Linked To Inflammaging Using Its Proprietary Stem Cell Therapy

Longeveron Inc., a clinical-stage biotechnology company focused on developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering the administration of the company’s proprietary Mesenchymal Stem Cells (MSCs) for treating symptoms associated with aging-related frailty.

The newly issued U.S. Patent No. 12,465,620, titled “Method of Treating Aging Frailty in Subjects with Inflammaging Using Human Mesenchymal Stem Cells,” provides Longeveron with patent protection in the United States through 2038. The company noted that additional patent term extensions and regulatory exclusivity protections could further extend this coverage in the future.

Aging-related frailty is a complex clinical syndrome characterized by the gradual decline of multiple physiological systems in older adults, leading to reduced healthspan and increased vulnerability. Common symptoms include weakness, fatigue, slowed mobility, reduced physical activity, and unintentional weight loss. Research has shown that chronic inflammation, or “inflammaging,” plays a significant role in the development of this condition by linking immune system changes to various age-related diseases and disorders.

Longeveron has previously conducted Phase 1 and Phase 2 clinical trials investigating its lead MSC-based therapy, laromestrocel, for aging-related frailty. These studies were designed to evaluate improvements in physical function, including endurance as measured by the six-minute walk test. The newly granted patent strengthens Longeveron’s intellectual property portfolio as the company continues to advance its research and development efforts aimed at improving quality of life and health outcomes for aging populations.